Sagent Pharmaceuticals (Sagent) is a privately held specialty pharmaceutical company engaged in the development, manufacturing, sourcing and marketing of pharmaceutical products, with a specific emphasis on injectable products. The company owns a unique, global network of resources, that comprises of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, resulting in quick yielding of an extensive portfolio of pharmaceutical products that meets the tailored needs of patients. It has also launched its vinorelbine injection, USP, a anti-mitotic chemotherapy drug, for which the company starts shipping immediately. Sagent comprises of about 200 products in the development stage. Recently, the company entered into an agreement with Actavis Inc., a generic pharmaceutical manufacure company, for the supply of the products in the US market. The company is headquartered at Schaumburg in Illinois, the US.